(Q34659473)

3 August 2017

0 references

1 reference

title

Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis (English)

1 reference

3 August 2017

1 reference

1 reference

George Tomlinson

3

0 references

Paula Rochon

object named as

Paula A Rochon

series ordinal

4

0 references

author name string

Mahyar Etminan

series ordinal

1

1 reference

3 August 2017

Mitchell A H Levine

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

American Journal of Medicine

3 August 2017

published in

1 reference

3 August 2017

volume

112

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

642-646

1 reference

Burden of migraine in the United States: disability and economic costs.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Current options for the prevention and treatment of migraine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Efficacy of nimodipine in comparison with pizotifen in the prophylaxis of migraine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Angiotensin II receptor antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Meta-analysis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Meta-analysis in clinical research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

HEpiMA: software for the identification of heterogeneity in meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Safety of irbesartan in the treatment of mild to moderate systemic hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Tolerability of a modern antihypertensive agent: candesartan cilexetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Efficacy of valsartan in patients aged > or =65 years with systolic hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study. Tasosartan Investigators Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Tolerability profile of tasosartan, a long-acting angiotensin II AT1 receptor blocker, in the treatment of patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Verapamil in migraine prophylaxis--a five-year review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Propranolol in the management of recurrent migraine: a meta-analytic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

Behavior of ambulatory blood pressure surrounding episodes of headache in mildly hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901100-2

10.1016/S0002-9343(02)01100-2

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference